Mavatar has announced the addition of networks of Alzheimer’s disease, glioma and other neurological disorders to its research platform, Mavatar Discovery, enabling researchers and pharmaceutical scientists to explore neurodegenerative disease biology at a systems level.
The new resource is being formally introduced to the scientific at the AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases taking place in Copenhagen right now 17-21 March 2026.
Mavatar Discovery is a data-driven research platform designed to help scientists move from gene lists to biological mechanisms.
By integrating thousands of transcriptomic datasets across diseases and tissues, the platform enables users to build gene-to-gene networks and explore how genes interact within biological systems.
This allows both academic researchers and pharmaceutical R&D teams to identify disease mechanisms, generate new hypotheses, and support target discovery.
Powered by Mavatar’s proprietary DINA (Deep Integrated Network Analysis) framework, the platform integrates large-scale molecular datasets to uncover biological relationships that may not be visible through traditional single-gene analysis. The newly integrated Alzheimer’s disease and general dementia networks allow users to investigate molecular interactions, regulatory pathways, and gene relationships associated with neurodegeneration within a broader biological context.
The launch is taking place in collaboration with leading Alzheimer’s researchers, including Tomas Deierborg, Professor of Experimental Medical Science at Lund University.
Early exploration of the platform has already produced promising insights.
The Alzheimer’s disease networks launched this week represent the first step in an expanding initiative. Mavatar plans to continue developing these networks together with input from leading researchers in the Alzheimer’s field.
